echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cancer Cell: Analysis of rare susceptibility mutations in lung cancer based on genome-wide analysis of 6,004 Chinese

    Cancer Cell: Analysis of rare susceptibility mutations in lung cancer based on genome-wide analysis of 6,004 Chinese

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Research Highlights:

    We conducted the largest non-small cell lung cancer (NSCLC) whole genome sequencing (WGS) study to date, with 6,004 Chinese individuals and 23,049 individuals


    We presented the largest non-small cell lung cancer (NSCLC) whole genome sequencing (WGS) study to date in 6,004 individuals of Chinese ancestry, and 23,049 individuals


    For the rare loss of function (LoF) variant (MAF < 0.


    These associations were validated


    Original Source:

    Wang C, Dai J, Qin N, Fan J, Ma H, Chen C et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.